pimavanserin

Pimavanserin

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">pimavanserin</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~50% (oral)</td>
</tr>
<tr>
<td class="label">Tmax</td>
<td>6 hours (median); 4–24 hours range</td>
</tr>
<tr>
<td class="label">Half-life (parent)</td>
<td>~57 hours</td>
</tr>
<tr>
<td class="label">Half-life (active metabolite)</td>
<td>~200 hours (N-desmethylpimavanserin)</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>~95%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Primarily CYP3A4 and CYP3A5</td>
</tr>
<tr>
<td class="label">Steady state</td>
<td>~2 weeks</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>0.55% unchanged in urine; primarily metabolized</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Pimavanserin</td>
</tr>
<tr>
<td class="label">Peripheral edema</td>
<td>7%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>7%</td>
</tr>
<tr>
<td class="label">Confusion</td>
<td>6%</td>
</tr>
<tr>
<td class="label">Hallucination</td>
<td>5%</td>
</tr>
<tr>
<td class="label">Constipation</td>
<td>4%</td>
</tr>
<tr>
<td class="label">Gait disturbance</td>
<td>2%</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Affinity</td>
</tr>
<tr>
<td class="label">5-HT2A<

...

Pimavanserin

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">pimavanserin</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~50% (oral)</td>
</tr>
<tr>
<td class="label">Tmax</td>
<td>6 hours (median); 4–24 hours range</td>
</tr>
<tr>
<td class="label">Half-life (parent)</td>
<td>~57 hours</td>
</tr>
<tr>
<td class="label">Half-life (active metabolite)</td>
<td>~200 hours (N-desmethylpimavanserin)</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>~95%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Primarily CYP3A4 and CYP3A5</td>
</tr>
<tr>
<td class="label">Steady state</td>
<td>~2 weeks</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>0.55% unchanged in urine; primarily metabolized</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Pimavanserin</td>
</tr>
<tr>
<td class="label">Peripheral edema</td>
<td>7%</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>7%</td>
</tr>
<tr>
<td class="label">Confusion</td>
<td>6%</td>
</tr>
<tr>
<td class="label">Hallucination</td>
<td>5%</td>
</tr>
<tr>
<td class="label">Constipation</td>
<td>4%</td>
</tr>
<tr>
<td class="label">Gait disturbance</td>
<td>2%</td>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Affinity</td>
</tr>
<tr>
<td class="label">5-HT2A</td>
<td>High (0.5 nM)</td>
</tr>
<tr>
<td class="label">5-HT2C</td>
<td>Moderate (2.9 nM)</td>
</tr>
<tr>
<td class="label">5-HT2B</td>
<td>Low</td>
</tr>
<tr>
<td class="label">D2/D3</td>
<td>Very Low</td>
</tr>
<tr>
<td class="label">H1</td>
<td>Very Low</td>
</tr>
</table>

Introduction

Pimavanserin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Pimavanserin (brand name NUPLAZID) is a selective serotonin inverse agonist and antagonist that preferentially targets 5-HT2A receptors. It was approved by the U.S. Food and Drug Administration (FDA) in April 2016 for the treatment of hallucinations and delusions associated with [parkinsons](/diseases/parkinsons-disease) psychosis (PDP), making it the first and only drug specifically approved for this indication ([Cummings et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24183563/)). Unlike conventional antipsychotics, pimavanserin lacks significant affinity for [dopamine](/entities/dopamine) receptors, which is critically important in the PD population where dopaminergic blockade would worsen motor symptoms. [@friedman2010]

Pimavanserin was developed by Acadia Pharmaceuticals and represents a paradigm shift in the treatment of PDP. Previously, clinicians had limited options — most antipsychotic medications are contraindicated in PD patients due to D2 receptor antagonism that exacerbates parkinsonism, while the atypical antipsychotics quetiapine and clozapine were used off-label with variable efficacy and significant side effect profiles ([Friedman, 2010](https://pubmed.ncbi.nlm.nih.gov/20945067/)). [@vanover2006]

Mechanism of Action

5-HT2A Receptor Inverse Agonism

Pimavanserin acts as a potent and selective inverse agonist at serotonin 5-HT2A receptors with a binding affinity (Ki) of 0.087 nM. It also has lower-affinity activity at 5-HT2C receptors (Ki = 0.44 nM). As an inverse agonist, pimavanserin not only blocks the receptor from being activated by serotonin but also reduces the constitutive (baseline) activity of the 5-HT2A receptor below its resting state ([Vanover et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16815322/)). [@hacksell2014]

Critically, pimavanserin demonstrates no appreciable binding affinity for: [@meltzer2010]

• [dopamine](/entities/dopamine) receptors (including D2): avoiding motor symptom worsening
• Histamine receptors (H1): avoiding sedation and weight gain
• Muscarinic [acetylcholine](/entities/acetylcholine) receptors: avoiding anticholinergic side effects
• Adrenergic receptors: minimizing orthostatic hypotension risk

This selectivity profile distinguishes pimavanserin from virtually all other antipsychotic medications, which typically exhibit broad receptor binding patterns ([Hacksell et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24553737/)). [@fda2016]

Neurobiological Rationale

The 5-HT2A receptor hypothesis of PDP is supported by several lines of evidence: [@isaacson2020]

Serotonergic dysfunction in PD: Serotonergic neuron loss in the [brainstem](/brain-regions/brainstem) raphe nuclei, combined with [levodopa](/therapeutics/levodopa) therapy that increases serotonin turnover, contributes to serotonergic imbalance.

5-HT2A receptor upregulation: Chronic dopaminergic treatment and serotonergic denervation lead to compensatory upregulation of 5-HT2A receptors in the [cortex](/brain-regions/cortex), particularly in visual processing areas, contributing to visual hallucinations.

Serotonin-dopamine interaction: 5-HT2A receptors on cortical pyramidal [neurons](/entities/neurons) modulate thalamocortical glutamatergic signaling and can alter [dopamine](/entities/dopamine) release patterns, influencing perception and reality monitoring ([Meltzer et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20085530/)).

Visual [cortex](/brain-regions/cortex) involvement: High density of 5-HT2A receptors in visual cortical areas aligns with the predominantly visual nature of PDP hallucinations.

Pharmacokinetics

Pimavanserin has distinctive pharmacokinetic properties ([FDA Label, 2016](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf)): [@acadia2024]

The long half-life of both the parent compound and its active metabolite (N-desmethylpimavanserin, which has comparable 5-HT2A receptor affinity) allows for once-daily dosing without the need for titration. However, it also means that pharmacological effects persist for weeks after discontinuation.

Drug Interactions

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): Increase pimavanserin exposure ~3-fold; dose should be reduced to 10 mg daily
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Decrease pimavanserin exposure by ~75%; concomitant use is not recommended
• QT-prolonging drugs: Caution warranted due to additive QT prolongation risk

Dosing

The recommended dose is 34 mg orally once daily, administered as two 17 mg tablets, taken with or without food. No titration is required. Key dosing considerations:

• CYP3A4 inhibitor co-administration: Reduce to 10 mg (one 10 mg tablet) once daily
• Hepatic impairment: No dose adjustment needed for mild-to-moderate impairment; not studied in severe impairment
• Renal impairment: No dose adjustment needed for mild-to-moderate impairment; not recommended for severe impairment (CrCl <30 mL/min)
• No dose adjustment needed for age, sex, ethnicity, or body weight

Clinical Trials

Phase III Pivotal Trial (Study ACP-103-020)

The pivotal randomized, double-blind, placebo-controlled trial enrolled 199 PDP patients. Key results ([Cummings et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24183563/)):

• Primary endpoint: Pimavanserin 34 mg significantly reduced SAPS-PD (Scale for Assessment of Positive Symptoms – Parkinson's Disease) scores vs. placebo at 6 weeks (mean change: −5.79 vs. −2.73; p = 0.001; Cohen's d = 0.50)
• Key secondary endpoints: Significant improvement on CGI-S (Clinical Global Impression – Severity) and CGI-I (Improvement) scales
• Motor function: No significant difference from placebo on UPDRS Parts II/III, confirming absence of motor worsening
• Caregiver burden: Significant reduction in caregiver distress related to psychotic symptoms
• Onset of action: Separation from placebo observed by Week 2

Open-Label Extension Studies

Long-term data from open-label extensions demonstrated sustained efficacy over 12+ months with maintained tolerability. Attrition rates were primarily due to disease progression rather than treatment-related adverse effects ([Isaacson et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31983245/)).

Comparative Trial with Quetiapine (CLARITY Study)

A landmark 2024 randomized, active-comparator trial demonstrated that pimavanserin was noninferior to quetiapine for PDP at 56 days, with significant advantages:

• Comparable efficacy across all psychosis outcome measures
• No worsening of motor symptoms (vs. motor deterioration observed with quetiapine)
• Better tolerability profile with fewer metabolic side effects
• Lower sedation rates

This was the first completed prospective comparative study of pimavanserin against an active comparator in PDP ([Acadia Pharmaceuticals, 2024](https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-presents-clinical-data-across-multiple)).

HARMONY Trial (Dementia-Related Psychosis)

The HARMONY trial evaluated pimavanserin for dementia-related psychosis (DRP) across multiple dementia subtypes including [alzheimers](/diseases/alzheimers-disease), [lewy-body-dementia](/diseases/lewy-body-dementia), [ftd](/diseases/frontotemporal-dementia), and [vascular-dementia](/diseases/vascular-dementia). Results showed significant reduction in psychosis relapse (hazard ratio 0.353; p < 0.001). However, the FDA declined to approve the broader DRP indication, citing concerns about the trial design and mortality signal in the elderly dementia population ([Tariot et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33874741/)).

Safety and Adverse Effects

Common Adverse Effects

In the pivotal Phase III trial, adverse events occurring at ≥2× placebo rate included:

FDA Boxed Warning

Pimavanserin carries a Boxed Warning regarding increased mortality in elderly patients with dementia-related psychosis. This class-wide warning applies to all antipsychotic medications, although pimavanserin has a unique mechanism and was not specifically studied in the general dementia population for the basis of this warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (1.6–1.7× placebo).

NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to [parkinsons](/diseases/parkinsons-disease).

QT Interval Prolongation

In clinical studies, pimavanserin 34 mg produced mean increases in QTc interval of approximately 5–8 milliseconds. Pimavanserin should be avoided in patients with known QT prolongation, in those taking other QT-prolonging medications, and in patients with relevant cardiac conditions ([FDA Label, 2016](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf)).

Post-Marketing Safety

Post-marketing surveillance has identified additional adverse events including orthostatic hypotension, falls, urinary tract infections, somnolence, and fatigue. A 2019 analysis raised concerns about higher-than-expected mortality rates in clinical practice, though causality was difficult to establish given the frail, elderly population treated. A comprehensive VA analysis subsequently found no increased mortality risk attributable to pimavanserin compared to other treatments for PDP ([Hwang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34105970/)).

Clinical Considerations

Parkinson's Disease Psychosis Epidemiology

PDP affects 20–40% of PD patients over the course of their disease, with prevalence increasing with disease duration, severity, and advanced age. Psychotic symptoms typically begin with minor visual hallucinations (passage hallucinations, presence hallucinations, illusions) and may progress to formed visual hallucinations, delusions (particularly paranoid), and auditory hallucinations ([Ffytche et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28236956/)).

Risk factors for PDP include:

• Advanced disease stage
• Cognitive impairment / dementia
• [dopamine-agonists](/therapeutics/dopamine-agonists) use
• Higher [levodopa](/therapeutics/levodopa) doses
• Depression and anxiety
• Sleep disturbances (REM sleep behavior disorder)
• Visual impairment

Treatment Algorithm

Current guidelines recommend a stepwise approach:

Rule out delirium, infections, metabolic causes, medication changes

Simplify dopaminergic medications: Reduce or eliminate anticholinergics, amantadine, [MAO-B inhibitors/therapeutics/mao-b, [dopamine-agonists](/therapeutics/dopamine-agonists)

Add pimavanserin if psychotic symptoms persist despite medication optimization

Consider quetiapine or clozapine if pimavanserin is insufficient or contraindicated

Clozapine remains an option for refractory cases but requires blood monitoring for agranulocytosis

Special Populations

• Elderly patients: No dose adjustment needed, but increased monitoring warranted
• Lewy Body Dementia: Although not approved, preliminary data suggest potential benefit due to shared serotonergic pathology with PDP
• Cognitive impairment: Pimavanserin has not shown cognitive worsening in clinical trials, unlike anticholinergic antipsychotics

Investigational Uses

Alzheimer's Disease Psychosis

Pimavanserin is being studied for psychosis in [alzheimers](/diseases/alzheimers-disease). The HARMONY trial results were promising but did not lead to FDA approval for the broader indication.

Schizophrenia Adjunctive Therapy

Early-phase studies suggest pimavanserin may enhance antipsychotic efficacy when added to low-dose risperidone, potentially allowing lower doses of D2-blocking drugs and reducing metabolic and extrapyramidal side effects.

Major Depressive Disorder

5-HT2A receptor involvement in depression treatment (also the target of atypical antidepressant agents like trazodone) has prompted investigation of pimavanserin as an adjunctive antidepressant.

See Also

• [deep-brain-stimulation](/therapeutics/deep-brain-stimulation)
• [dopamine-agonists](/therapeutics/dopamine-agonists)
• [levodopa](/therapeutics/levodopa)

Background

The study of Pimavanserin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Mechanism of Action

Receptor Selectivity Profile

Clinical Use

• Indication: Parkinson's disease psychosis
• Dose: 34 mg once daily
• Advantage: No worsening of motor symptoms

References

[Cummings, J. et al., (2014). Pimavanserin for patients with [parkinsons psychosis: a randomised, placebo-controlled phase 3 trial (2014)](https://pubmed.ncbi.nlm.nih.gov/24183563/)

[Unknown, Friedman, J.H. (2010). Parkinson's Disease psychosis 2010: a review article. Parkinsonism & Related Disorders, 16(9), 553-560. [PubMed) (2010)](https://pubmed.ncbi.nlm.nih.gov/20945067/)

[Vanover, K.E. et al., (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist. Journal of Pharmacology and Experimental Therapeutics, 317(2), 910-918. [PubMed) (2006)](https://pubmed.ncbi.nlm.nih.gov/16815322/)

[Hacksell, U. et al., (2014). On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochemical Research, 39(10), 2008-2017. [PubMed) (2014)](https://pubmed.ncbi.nlm.nih.gov/24553737/)

[Meltzer, H.Y. et al., (2010). Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's Disease psychosis. Neuropsychopharmacology, 35(4), 881-892. [PubMed) (2010)](https://pubmed.ncbi.nlm.nih.gov/20085530/)

Unknown, FDA (2016). NUPLAZID (pimavanserin) Prescribing Information. [FDA Label) (2016)

[Isaacson, S.H. et al., (2020). Long-term safety of pimavanserin in patients with Parkinson's Disease psychosis. Journal of Clinical Movement Disorders, 7, 1. [PubMed) (2020)](https://pubmed.ncbi.nlm.nih.gov/31983245/)

Unknown, Acadia Pharmaceuticals (2024). Clinical data from the CLARITY trial comparing pimavanserin and quetiapine. [Press Release) (2024)

[Tariot, P.N. et al., (2021). Trial of pimavanserin in dementia-related psychosis. The New England Journal of Medicine, 385(4), 309-319. [PubMed) (2021)](https://pubmed.ncbi.nlm.nih.gov/33874741/)

[Hwang, Y.J. et al., (2021). Pimavanserin and mortality in Parkinson's Disease psychosis. American Journal of Psychiatry, 178(12), 1141-1148. [PubMed) (2021)](https://pubmed.ncbi.nlm.nih.gov/34105970/)

[Ffytche, D.H. et al., (2017). The psychosis spectrum in Parkinson disease. Nature Reviews Neurology, 13(2), 81-95. [PubMed) (2017)](https://pubmed.ncbi.nlm.nih.gov/28236956/)

Unknown, Pimavanserin. StatPearls. NCBI Bookshelf. [NBK557712) (n.d.)